The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Khoroshilova-Maslova I.P.

Helmholtz National Medical Research Center of Eye Diseases

Leparskaya N.L.

Helmholtz National Medical Research Center of Eye Diseases

Alpeeva E.V.

Koltzov Institute of Developmental Biology of Russian Academy of Sciences

Voroteliak E.A.

Koltzov Institute of Developmental Biology of Russian Academy of Sciences

Melfalan in the treatment of proliferative vitreoretinopathy (experimental study)

Authors:

Khoroshilova-Maslova I.P., Leparskaya N.L., Alpeeva E.V., Voroteliak E.A.

More about the authors

Journal: Russian Annals of Ophthalmology. 2020;136(4): 19‑25

Read: 3219 times


To cite this article:

Khoroshilova-Maslova IP, Leparskaya NL, Alpeeva EV, Voroteliak EA. Melfalan in the treatment of proliferative vitreoretinopathy (experimental study). Russian Annals of Ophthalmology. 2020;136(4):19‑25. (In Russ.)
https://doi.org/10.17116/oftalma202013604119

References:

  1. Pastor JC, de la Rua ER, Martin F. Proliferative vitreoretinnopathy: risk factors and pathobiology. Prog Retin Eye Res. 2002;21(1):127-144.  https://doi.org/10.1016/s1350-9462(01)00023-4
  2. Pastor JC, Rodriguez E, Marcos M, et al. Combined pharmacologic therapy in a rabbit model of proliferative vitreoretinopathy (PVR). Ophthalmic Res. 2000;32:25-29.  https://doi.org/10.1159/000055583
  3. Asaria RH, Kon CH, Bunce C, Charteris DG, Wong D, et al. How to predict proliferative vitreoretinopathy. A prospective study. Ophthalmology. 2001;108:1184-1186. https://doi.org/10.1016/s0161-6420(01)00553-x
  4. Jonas JB, Hayler JK, Panda-Jonas S. Intravitreal inlection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol. 2000;84:1064-1067. https://doi.org/10.1136/bjo.84.9.1064
  5. Sundaram V, Barsam A, Vergili G. Intravitral low molecular weight heparin and 5-fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery. Cochrane Database Syst Rev. 2010;7: CD006421. https://doi.org/10.1002/14651858.cd006421.pub2
  6. Kumar A, Nainiwal S, Choudbary I, Tewari HK, Verma LK. Role of daunorubicin in inhibiting proliferative vitreoretinopathy after retinal detachment surgery. Clin Experiment Ophthalmol. 2002;30(5):348-351.  https://doi.org/10.1046/j.1442-9071.2002.00554.x
  7. Daniels SA, Coonley KG, Yoshizumi MO. Taxol treatment of experimental proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol. 1990; 228(6):513-516.  https://doi.org/10.1007/bf00918482
  8. Berman DH, Gombe GM. Proliferative vitreoretinopathy: does oral low-dose colchicine have an inhibitory effect? A controlled study in humans. Ophthalmic Surg. 1989;20(4):268-272. 
  9. Chang YC, Hu DN, Wu WC. Effect of oral 13-cis-retinoic acid treatment on postoperative clinical outcome of eyes with proliferative vitreoretinopathy. Am J Ophthalmolol. 2008;146(3):440-446.  https://doi.org/10.1016/j.ajo.2008.05.002
  10. Liang CM, Tai MC, Chang YH, et al. Glucosamine inhibits epithelial-to-mesenchymal transition and migration of retinal pigment epithelium cells in culture and morphologic changes in mouse model of proliferative vitreoretinopathy. Acta Ophthalmol. 2011;89(6):505-514.  https://doi.org/10.1111/j.1755-3768.2011.02147.x
  11. Schiff WM, Hwang JC, Ober MD, et al. Safety and efficacy assessment of chimeric ribozyme to proliferating cell nuclear antigen to prevent recurrence of proliferative vitreoretinopathy. Arch Ophthalmol. 2007;125(9):1161-1167. https://doi.org/10.1001/archopht.125.9.1161
  12. Kuo HK, Wu PC, Yang PM, Chen YH, Wu YC, Hu DN. Effects of topoisomerase II inhibitors on retinal pigment epithelium and experimental proliferative vitreoretonopathy. J Ocul Pharmacol Ther. 2007;23(1):14-20.  https://doi.org/10.1089/jop.2006.0059
  13. Borhani H, Peyman GA, Rahimy MH, Thompson H. Supression of experimental proliferative vitreoretinopaty by sustained intraocular delivery of 5-FU. Int Ophthalmol. 1995;19(1):43-49.  https://doi.org/10.1007/bf00156419
  14. Charteris DG. Proliferative vitreoretinopathy pathology, surgical management and adjunctive treatment. Br J Ophthalmol. 1995;79:953-960.  https://doi.org/10.1136/bjo.79.10.953
  15. Asaria RH, Kon CH, Bunce C, et al. Adjuvant 5-ftuorouracil and heparin prevents proliferative vitreoretinopathy: resulta from a randomized, double-blind controlled clinical trial. Ophthalmology. 2000;108(7):1179-1183. https://doi.org/10.1016/s0161-6420(01)00589-9
  16. Wickham L, Bunce C, Wong D, McGurn D, Charteris DG. Randomized controlled trial of combined 5-fluoroouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy. Ophthalmology. 2007;114(4):698-704.  https://doi.org/10.1016/j.ophtha.2006.08.042
  17. Sundaram V, Barsam A, Vergili G. Intravitral low molecular weight heparin and 5-fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery. Cochrane Database Syst Rev. 2010; 7:CD006421. https://doi.org/10.1002/14651858.cd006421.pub2
  18. Wickham L, Bunce C, Wong D, McGurn D, Charteris DG. Randomized controlled trial of combined 5-fluoroouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy. Ophthalmology. 2007;114(4):698-704.  https://doi.org/10.1016/j.ophtha.2006.08.042
  19. Francis J, Schaiquevich P, Buiatrago E. Local and systemic toxicity of intravitreal melphalan for vitreous seeding in retinoblastoma: a preclinical and clinical study. Ophthalmology. 2014;121(9):1810-1817. https://doi.org/10.1016/j.ophtha.2014.03.028
  20. Chassemi F, Shields C. Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma. Arch Ophthalmol. 2012;130(10):1268-1271. https://doi.org/10.1001/archophthalmol.2012.1983
  21. Saakyan SV, Zharua A. Rezul’taty lecheniya rezistentnykh i daleko zashedshikh form retinoblastomy s pomoshch’yu superselektivnoi intraarterial’noi terapii. Onkopediatriya. 2015;2(3):333-334. (In Russ.).
  22. Saakyan SV, Myakoshina EB, Polyakov VG, Ushakova TL, Ismailova DM. Maculopathy and chorioretinopathy in children with retinoblastoma receiving chemotherapy: clinical trials and morphometric analysis. Rossiiskaya pediatricheskaya oftal’mologiya. 2018;13(4):167-175. (In Russ.).
  23. Francis J, Marr B, Brodie S. Anterior ocular toxicity of intravitreous melphalan for retinoblastoma. JAMA Ophthalmol. 2015;133(12):1459-1463. https://doi.org/10.1001/jamaophthalmol.2015.3119
  24. Shaiquevich P, Buitrago E, Taich A. Pharmacokinetic analisis of melphalan after superselective ophthalmic artery infusion in preclinic models and retinoblastoma patients. Invest Ophthalmol Vis Sci. 2012;53(7):4205-4512. https://doi.org/10.1167/iovs.12-9501
  25. Khoroshilova-Maslova IP, Leparskaya NL. Retinal changes after intravitreal injections of various concentrations of antiproliferative medication Melphalan: an experimental and morphological study. Rossiiskii oftal’mologicheskii zhurnal = Russian Ophthalmological Journal. 2018;11(1):36-40. (In Russ.). https://doi.org/10.21516/2072-0076-2018-11-1-36-40
  26. Horoshilova-Maslova IP, Leparskaya NL, Voroteljak EA, Vasileva AV. The significance of fibroblasts in experimental modeling of proliferative vitreoretinopathy. Vestnik oftal’mologii. 2017;133(5):4-10. (In Russ.). https://doi.org/10.17116/oftalma201713354-10
  27. Francis J, Marr B, Brodie S. Anterior ocular toxicity of intravitreous melphalan for retinoblastoma. JAMA Ophthalmol. 2015;133(12):1459-1463. https://doi.org/10.1001/jamaophthalmol.2015.3119
  28. Shaiquevich P, Buitrago E, Taich A. Pharmacokinetic analisis of melphalan after superselective ophthalmic artery infusion in preclinic models and retinoblastoma patients. Invest Ophthalmol Vis Sci. 2012;53(7):4205-4212. https://doi.org/10.1167/iovs.12-9501
  29. Khoroshilova IP, Leparskaya NL. Sposob lecheniya proliferativnykh protsessov zadnego otrezka glaza. Patent RF na izobretenie №2684927/16.04.19. Byul. № 11. Accessed 18.06.2019. (In Russ.). https://www1.fips.ru/iiss/document.xhtml?faces-redirect=true&id=cb51423de6551d27ef32016e7e6b8806

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.